Highest-materiality recent filing
Balchem Q1 net sales $270.7M (+8.1%); adjusted EBITDA $74.3M (+12.1%)
Net sales $270.7M, up 8.1% YoY; GAAP EPS $1.25, adjusted EPS $1.33.
Q4 net sales $263.6M (+9.8% YoY); GAAP EPS $1.21 vs $1.03; adjusted EPS $1.31 vs $1.13.
Balchem declares $0.96 annual dividend (10.3% increase), authorizes repurchase of up to 4M shares
Dividend of $0.96 per share declared on Dec 9, 2025, payable Jan 20, 2026 to holders of record Dec 23, 2025.
Balchem Q3 2025: record sales $267.6M, adj. EPS $1.35, all segments grow
Record net sales $267.6M (+11.5% YoY); GAAP EPS $1.24 vs $1.03; adjusted EPS $1.35 vs $1.13.
Balchem Q2 2025: record net sales $255.5M, adj. EPS $1.27 beat
Net sales $255.5M, +9.1% YoY; GAAP EPS $1.17 vs $0.98 prior year quarter.
Balchem Q1 net sales $250.5M record; adj. EPS $1.22 vs $1.03 YoY; all segments grow
Net sales of $250.5M, up 4.5% YoY; GAAP EPS $1.13 vs $0.89; adjusted EPS $1.22 vs $1.03.
Balchem Q4 record net sales $240M, adjusted EBITDA $62.8M, EPS $1.03
Q4 net sales record $240.0M (+4.9% YoY); GAAP EPS $1.03 vs $0.82; adjusted EPS $1.13 vs $0.95.
Balchem Q3 net sales up 4.3% to $239.9M; record adjusted EBITDA $64.4M, up 7.6% YoY
GAAP EPS $1.03 versus $0.90 prior year; adjusted EPS record $1.13 versus $1.04.
Balchem Q2 net sales $234.1M (+1.2% YoY); record adjusted EBITDA $62.3M (+5.0%)
GAAP EPS $0.98 vs $0.93; adjusted EPS $1.09 vs $1.06.
Balchem reports record Q1 net sales of $239.7M, adjusted EBITDA up 8%
Net sales $239.7M (+3.1% YoY), adjusted EBITDA $60.9M (+8.0% YoY), both all-time records.
William A. Backus, Vice President and Chief Accounting Officer, has notified the Company of his intent to retire from his position on March 31, 2026.
On October 16, 2024, the Corporate Governance and Nominating Committee of the Balchem Corporation (“Balchem”) Board of Directors (the “Board”) accepted the resignation of Joyce Lee as a Director.
Max materiality 0.75 · Median 0.65 · Most common event earnings